 |
|
|
| |
Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions With the
Farnesoid X Receptor Agonist GS-9674, and Phenotypic Probe Substrates and Inhibitors/Inducers
|
| |
| |
Reported by Jules Levin
EASL - International Liver Congress™, 19-23 April 2017, Amsterdam, the Netherlands
Cara H. Nelson, Brian J. Kirby, Gong Shen, C. Stephen Djedjos, Robert P. Myers, Deqing Xiao, Charisma Swartzburg, Anita Mathias
Gilead Sciences, Inc., Foster City, California, USA
FXR AGONISM BY GS-9674 DECREASES STEATOSIS AND FIBROSIS IN A MURINE MODEL OF NASH - (12/02/16)
EASL: Pharmacokinetics of Selonsertib, GS-9674, and/or GS-0976 in Combination in Healthy Subjects - (05/23/17)
Evaluation of the Safety and Pharmacokinetics of the Oral, Nonsteroidal Farnesoid X Receptor Agonist GS-9674 in Healthy Volunteers - (11/29/16)
GS-4997, an Inhibitor of Apoptosis Signal-Regulating Kinase (ASK1), Alone or in Combination with Simtuzumab for the Treatment of Nonalcoholic Steatohepatitis (NASH): A Randomized, Phase 2 Trial - (11/21/16)
Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD) - (10/21/16)
Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors - (12/01/16)
|
| |
|
|
|
|
|
